🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Shire bails on GvHD candidate G1-AAT IV in U.S., licensor Kamada down 8% premarket

Published 06/07/2017, 07:36 AM
© Reuters.  Shire bails on GvHD candidate G1-AAT IV in U.S., licensor Kamada down 8% premarket
KMDA
-
SHPG
-
  • Prompted by slow recruitment in the first part of a Phase 2/3 study and other pipeline priorities, Shire plc (NASDAQ:SHPG) transfers its IND for Graft-Versus-Host Disease (GvHD) candidate Alpha-1 Antitrypsin (G1-AAT IV) to Kamada Ltd . (NASDAQ:KMDA), who is developing the product in the EU.
  • Shire has stopped the U.S. study. Kamada will resume U.S. development in the next few months after standardizing the study design.
  • G1-AAT IV has Orphan Drug status in both the U.S. and EU for the indication.
  • Kamada and Shire (Baxter at the time) inked an agreement in 2010 for Kamada's IV AAT under which Shire has exclusive rights in the U.S., Canada, Australia and New Zealand. The companies will continue to collaborate on developing AAT IV for prevention of lung transplant rejection.
  • Kamada is down 8% premarket on light volume.
  • Now read: Shire Is Significantly Undervalued


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.